Effects of high dose medroxyprogesterone acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma.
In 18 patients, 12 with renal cell and 6 with prostatic carcinoma treatment with high dose medroxyprogesterone acetate (MPA) significantly increased serum antithrombin III and haptoglobin concentrations. During treatment the proteins correlated with each others suggesting a response to similar regulatory mechanisms. Levels of orosomucoid, a1-antitrypsin, C1-inhibitor and von Willebrand factor did not change during treatment showing that the increase of haptoglobin was not due to an acute-phase response. The increased antithrombin III levels may have a favourable impact on the frequency of thromboembolic complications during treatment with MPA.
Nilsson
T K
TK
Department of Urology & Andrology, University of Umeå, Sweden.
Tomic
R
R
Ljungberg
B
B
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000990:Antithrombin III / Q000187:drug effects*; D001798:Blood Proteins / Q000187:drug effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D006242:Haptoglobins / Q000187:drug effects*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001798:Blood Proteins; D003692:Delayed-Action Preparations; D006242:Haptoglobins; D000990:Antithrombin III; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone